Humacyte (HUMA) vs Inovio Pharmaceuticals (INO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Inovio Pharmaceuticals (INO) has outperformed Humacyte (HUMA) over the past year, losing 57.4% versus a loss of 73.5%. Over five years, HUMA leads with a -95.6% price change compared with -98.7% for INO. Humacyte is the larger company by market cap ($124.2 million vs $112.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUMA | INO |
|---|---|---|
| Share price | $0.4471 | $1.09 |
| Market cap | $124.20M | $112.70M |
| 1-day change | -5.34% | -5.63% |
| YTD return | -53.48% | -37.36% |
| 1-year return | -73.54% | -57.42% |
| 5-year return | -95.63% | -98.71% |
| EPS (TTM) | $-0.51 | $-0.90 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.90 | $2.72 |
| 52-week low | $0.4367 | $0.56 |
| Distance from 52-week high | -76.41% | -59.93% |
| Analyst consensus | buy | none |
| Avg. price target upside | +264.57% | +190.83% |
| Average volume | 6.30M | 3.86M |
| Shares outstanding | 277.80M | 103.40M |
| Employees | 184 | 112 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INO has outperformed HUMA by 16.1 percentage points over the past year.
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Healthcare · Biotechnology · 184 employees
About Inovio Pharmaceuticals
INO stock →Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses SynCon, to help engineer precisely designed plasmid DNA plasmids, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids.
Healthcare · Biotechnology · 112 employees
HUMA vs INO FAQ
Which is bigger, Humacyte or Inovio Pharmaceuticals?
Humacyte (HUMA) is larger, with a market capitalization of $124.20M compared with $112.70M for Inovio Pharmaceuticals (INO).
Which stock has performed better over the past year, HUMA or INO?
INO returned -57.42% over the past 12 months, compared with -73.54% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Humacyte and Inovio Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.